List of Excipients in Branded Drug EVENITY

EVENITY Excipient Strategy and Commercial Opportunities for Romosozumab

Last updated: September 24, 2026

EVENITY is a refrigerated, subcutaneous biologic containing romosozumab-aqqg, a humanized monoclonal antibody against sclerostin. Its commercial formulation uses a relatively short excipient system: histidine-based buffering, calcium chloride for tonicity and formulation support, polysorbate 20 as a surfactant, sodium hydroxide for pH adjustment, and water for injection. The main commercial opportunities are in high-purity biologic-grade excipients, low-peroxide polysorbate 20, formulation analytics, container-closure systems, prefilled syringe components, and biosimilar development.

The product is supplied as two 105 mg/1.17 mL prefilled syringes administered once monthly for a total 210 mg dose. The U.S. formulation is a 90 mg/mL solution with a target pH of approximately 5.2 and storage at 2°C to 8°C. The FDA approved EVENITY on April 9, 2019, under Biologics License Application 761062. [1]

What excipients are used in the EVENITY formulation?

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation role	Commercial relevance
Histidine	Buffering and pH control	High-purity amino acid and low-bioburden supply
Calcium chloride dihydrate	Ionic strength and tonicity adjustment	Compendial inorganic salt with tight impurity control
Polysorbate 20	Surfactant; limits interfacial aggregation and adsorption	Highest formulation-risk excipient
Sodium hydroxide	pH adjustment	Low-cost but quality-critical processing input
Water for injection	Solvent	Sterile manufacturing and endotoxin control

The label does not identify a preservative. The product is administered from single-use prefilled syringes, which reduces the need for antimicrobial preservation. [1]

Why is polysorbate 20 strategically important?

Polysorbate 20 is the most technically sensitive excipient in the formulation. Monoclonal antibodies can adsorb to air-liquid, liquid-solid, and silicone-oil interfaces. Polysorbate 20 reduces this interfacial stress, but it can also undergo hydrolysis and oxidation. Degradation products may include free fatty acids, peroxides, and other species that can affect antibody aggregation, visible and subvisible particles, potency, and syringe compatibility.

For EVENITY or a romosozumab biosimilar, excipient suppliers with strong control over the following attributes have a commercial advantage:

• Peroxide concentration
• Free fatty acid profile
• Residual ethylene oxide or related process impurities
• Lot-to-lot molecular distribution
• Bioburden and endotoxin
• Oxidative stability
• Compatibility with silicone-oil-lubricated syringes
• Extractables and leachables profile

The opportunity is not limited to supplying standard polysorbate 20. Suppliers can differentiate through low-peroxide grades, stabilized grades, high-purity recombinant or synthetic alternatives, and analytical packages that support comparability and regulatory filings.

What is the role of histidine and calcium chloride?

Histidine provides buffering near the mildly acidic pH used for the formulation. Histidine can be supplied as the free amino acid or combined with histidine hydrochloride, depending on the manufacturing process and target buffer capacity. The U.S. label lists histidine and sodium hydroxide, while regional product information may describe the buffer system differently because of nomenclature conventions and manufacturing documentation. [1,2]

Calcium chloride dihydrate contributes to ionic strength and tonicity. Calcium can also affect protein electrostatic interactions and aggregation behavior. Its use creates a requirement for tight control of elemental impurities, particulate matter, endotoxin, and concentration accuracy.

Neither histidine nor calcium chloride is likely to be the principal value driver in the formulation. Their commercial importance lies in consistency, regulatory documentation, and validated supply rather than material scarcity.

How does the EVENITY formulation affect manufacturing and supply-chain strategy?

EVENITY is a high-concentration biologic solution administered by prefilled syringe. The formulation strategy must therefore control both protein stability and delivery-device compatibility.

Key manufacturing considerations include:

1. Preparation of a low-bioburden excipient solution.
2. Control of polysorbate degradation before antibody exposure.
3. Low-shear mixing and minimized air entrainment.
4. Sterile filtration without excessive protein or surfactant interaction.
5. Compatibility with the syringe barrel, stopper, needle shield, and silicone lubricant.
6. Control of visible and subvisible particles.
7. Refrigerated storage and shipment.
8. Management of a two-syringe monthly dose.

The two-syringe presentation creates a commercial opportunity for device and packaging suppliers. A single 210 mg administration would require a different delivery platform, such as a higher-capacity prefilled syringe, dual-chamber device, or autoinjector. Any reformulation would need to preserve exposure, injection volume, viscosity, stability, and human-factors performance.

What formulation patents and manufacturing IP protect romosozumab products?

Romosozumab is a biologic, so its intellectual-property position can include antibody sequence claims, antigen-binding claims, production-cell and manufacturing claims, formulation claims, dosing claims, and device or container-closure claims.

The commercial formulation may be protected by confidential know-how even where a particular excipient combination is not covered by a currently visible product-specific patent. Relevant know-how can include:

• Polysorbate grade and supplier qualification
• Excipient order of addition
• Mixing conditions
• Hold times
• Filtration parameters
• Protein concentration and pH windows
• Syringe siliconization specifications
• Freeze-thaw and shipping controls
• Particle-control methods
• Potency and aggregation assays

A biosimilar developer would not necessarily need to reproduce every excipient concentration. FDA biosimilar guidance allows differences in inactive ingredients where the product remains highly similar and the differences do not affect safety, purity, or potency. [3] In practice, changes to polysorbate type, buffer system, calcium concentration, or container-closure materials can increase analytical and clinical comparability burdens.

EVENITY is regulated as a biologic and is not listed in the FDA Orange Book as a small-molecule drug. Its reference-product and biosimilar information is handled through the Purple Book framework. [4]

When does EVENITY lose regulatory exclusivity?

EVENITY received U.S. approval on April 9, 2019. Under the Biologics Price Competition and Innovation Act, the reference product generally receives 12 years of U.S. reference-product exclusivity from first licensure, subject to statutory adjustments. The principal U.S. exclusivity date is therefore approximately April 9, 2031. A biosimilar applicant could begin certain premarket activities after four years, approximately April 9, 2023, but commercial approval and launch depend on regulatory and patent outcomes. [4,5]

Event	Date or period
FDA approval of EVENITY	April 9, 2019
Four-year biosimilar filing barrier	Approximately April 9, 2023
Twelve-year reference-product exclusivity	Approximately April 9, 2031
Administration	210 mg subcutaneously once monthly
U.S. reference product	EVENITY, romosozumab-aqqg
Regulatory pathway for follow-on products	351(k) biosimilar pathway

Regulatory exclusivity does not establish a guaranteed commercial launch date. Patent claims, litigation, settlements, manufacturing readiness, interchangeability strategy, and payer access can move market entry later.

What generic or biosimilar entry risks exist for EVENITY?

Traditional generic substitution is not the relevant pathway because EVENITY is a monoclonal antibody. The competitive risk comes from biosimilars and potentially from alternative osteoporosis therapies.

A romosozumab biosimilar developer would face several technical barriers:

• Demonstrating analytical similarity for a complex antibody
• Matching or explaining glycosylation and charge variants
• Establishing comparable binding to sclerostin
• Controlling aggregation and particles
• Demonstrating comparable potency and immunogenicity risk
• Matching the prefilled syringe performance
• Building a refrigerated commercial supply chain
• Addressing the monthly two-syringe dose burden

The excipient system itself is not likely to block biosimilar entry. The greater risk is the interaction between excipients, protein quality attributes, and the delivery system. Polysorbate selection can influence aggregation and particle formation, while syringe materials can affect adsorption and leachables. FDA’s biosimilar framework evaluates the total product, not only the active antibody sequence. [3]

What commercial opportunities exist for EVENITY excipient suppliers?

Low-peroxide polysorbate 20

This is the strongest excipient opportunity. Suppliers can compete on:

• Oxidative stability
• Lot consistency
• Reduced hydrolysis
• Pharmaceutical-grade documentation
• Global regulatory support
• Long-term supply assurance
• Compatibility with monoclonal antibody formulations

Large excipient manufacturers and specialty chemical suppliers can capture value through dual sourcing, custom specifications, and technical-service agreements.

Histidine and calcium chloride

These materials are established commodities, but biologics manufacturers pay for qualified, reliable supply. Suppliers can create value through:

• Compendial compliance
• Low endotoxin grades
• Animal-origin-free documentation
• Global change-control discipline
• Small-volume sterile or ready-to-use solutions
• Integrated formulation-buffer services

Analytical and stability services

Testing providers can support EVENITY-like products through:

• Polysorbate degradation analysis
• Peroxide and free-fatty-acid testing
• Subvisible particle characterization
• Protein aggregation assays
• Extractables and leachables studies
• Forced-degradation programs
• Container-closure integrity testing
• Shipping and temperature-excursion studies

The market is strongest where excipient performance is linked directly to biologic quality attributes.

Prefilled syringe and device components

The product’s two-syringe presentation creates demand for:

• Low-silicone or silicone-controlled syringes
• Low-particulate elastomeric stoppers
• Needle shields with reduced extractables
• Human-factors engineering
• Autoinjector conversion platforms
• Higher-volume delivery systems

A device supplier that enables a one-syringe monthly dose could compete on convenience and administration burden, but such a change would require substantial comparability, usability, stability, and regulatory work.

How does EVENITY compare with competing osteoporosis products?

Product	Active ingredient	Modality	Administration	Excipient and device implications
EVENITY	Romosozumab	Monoclonal antibody	Two subcutaneous syringes monthly	Strong dependence on polysorbate, syringe compatibility, refrigerated logistics
Prolia	Denosumab	Monoclonal antibody	One subcutaneous injection every six months	Similar biologic excipient risks, lower annual injection frequency
Forteo	Teriparatide	Peptide	Daily injection	Different stability, preservation, and device requirements
Tymlos	Abaloparatide	Peptide	Daily injection	Pen-device and multidose formulation considerations
Reclast	Zoledronic acid	Small molecule	Intravenous infusion	No monoclonal-antibody surfactant problem; infusion logistics dominate

EVENITY competes with denosumab on biologic manufacturing and excipient complexity. Denosumab’s six-month dosing interval can be commercially attractive to patients and providers, while EVENITY’s monthly administration creates more recurring device and cold-chain demand. For suppliers, the market opportunity is therefore tied to repeat monthly dosing rather than only annual treatment volume.

What FDA regulatory status and Orange Book status apply to EVENITY?

EVENITY is FDA-approved for treatment of osteoporosis in postmenopausal women at high risk for fracture, including patients with a history of osteoporotic fracture or multiple risk factors for fracture. The label carries a boxed warning concerning increased risk of myocardial infarction, stroke, and cardiovascular death. [1]

Because EVENITY is a biologic, the FDA Purple Book is the relevant reference for biologic exclusivity and biosimilar competition. The Orange Book is designed primarily for approved drug products, patent listings, and exclusivity information associated with small-molecule applications. It is not the primary patent-listing source for BLA biologics. [4]

How strong is the excipient-related patent position?

The excipient-related position is likely stronger as manufacturing know-how and product-quality control than as a standalone barrier based on histidine, calcium chloride, or polysorbate 20. These excipients are widely used in biologics and generally cannot support broad exclusivity by themselves.

Potentially stronger protection may arise from:

• Narrow formulation ranges
• Specific surfactant concentrations
• Low-particle compositions
• Stabilized antibody formulations
• Container-closure combinations
• Device integration
• Manufacturing processes that reduce aggregation
• Method-of-use claims tied to dosing and patient selection

For commercial diligence, the relevant distinction is between published formulation claims and operational know-how. A biosimilar may design around a formulation claim but still need to reproduce the product’s stability profile. That can preserve commercial value for excipient suppliers, contract manufacturers, and analytical service providers even after core biologic patents expire.

What licensing and partnership opportunities are available?

The most realistic opportunities are platform and supply agreements rather than licenses to the EVENITY formulation itself. Potential counterparties include:

• Polysorbate manufacturers with low-peroxide technology
• CDMOs with monoclonal-antibody fill-finish capacity
• Prefilled syringe and autoinjector manufacturers
• Analytical laboratories specializing in biologic comparability
• Cold-chain logistics providers
• Biosimilar developers targeting romosozumab
• Suppliers of animal-origin-free and chemically characterized excipients

Licensing value would increase if a supplier owns validated technology for reducing polysorbate oxidation, controlling particles, or enabling a higher-concentration romosozumab formulation. A standard supply contract for histidine or calcium chloride would usually have lower strategic value than a formulation-control platform tied to product stability.

Key Takeaways

• EVENITY contains romosozumab-aqqg with histidine, calcium chloride dihydrate, polysorbate 20, sodium hydroxide, and water for injection.
• Polysorbate 20 is the highest-value excipient from a technical and commercial perspective.
• The principal risks are oxidation, hydrolysis, aggregation, particles, and container-closure interaction.
• The two-syringe monthly presentation creates opportunities for syringe, autoinjector, and higher-volume delivery technologies.
• EVENITY is regulated as a biologic. The Purple Book, not the Orange Book, is the relevant framework for biosimilar competition and biologic exclusivity.
• U.S. reference-product exclusivity runs approximately through April 9, 2031, subject to statutory treatment of the original licensure.
• Histidine and calcium chloride are lower-margin but strategically important qualified materials.
• Manufacturing know-how, excipient specifications, analytical methods, and device compatibility may be more commercially important than broad standalone excipient patents.
• The most attractive supplier opportunities are low-peroxide polysorbate 20, biologic-grade excipient systems, particle-control analytics, and prefilled syringe technologies.

FAQs

Is polysorbate 20 essential to the EVENITY formulation?

The U.S. label identifies polysorbate 20 as an inactive ingredient. A biosimilar developer could use a different surfactant only if it establishes adequate similarity, stability, safety, purity, and potency.

Can a company sell an EVENITY biosimilar before 2031?

Regulatory filing activity can begin before 2031 under the BPCIA framework, but reference-product exclusivity, patent claims, litigation, settlements, and FDA approval can delay commercial launch.

Are EVENITY excipients patented individually?

Histidine, calcium chloride, polysorbate 20, sodium hydroxide, and water for injection are established excipients. Commercial protection is more likely to involve specific formulation ranges, processing conditions, analytical controls, or device combinations.

Does the two-syringe dose create a commercial disadvantage?

It can increase administration burden, packaging requirements, and device costs relative to products delivered in one syringe. It also creates opportunities for higher-volume syringes, autoinjectors, and integrated delivery systems.

Which excipient has the greatest supply-chain risk?

Polysorbate 20 has the greatest formulation and quality risk because oxidation and hydrolysis can affect antibody stability and particulate formation. Histidine and calcium chloride are generally easier to source but still require qualified pharmaceutical-grade supply.

References

1. U.S. Food and Drug Administration. (2024). EVENITY (romosozumab-aqqg) injection, prescribing information.
2. European Medicines Agency. (2024). Evenity: EPAR product information.
3. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
5. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §§ 7001-7003.